aspirin & colorectal polyps

Introduction

randomized, double blind, placebo-controlled trials

#1

• 635 patients with previously resected colorectal carcinoma
• 31 month follow-up
• aspirin 325 mg QD vs placebo
• 1-2 colonoscopies
• aspirin recipients significantly less liekly to develop 2 or
• more adenomatous polyps (17% vs 37%)
• adverse effects similar in both groups

#2

• 1121 patients with previously resected adenomatous polyp
• 31 month average follow-up
• aspirin 81 mg, 325 mg or placebo
• at least 1 adenoma detected in
  • 38% (81 mg QD aspirin)*
  • 45% (325 mg QD aspirin)
  • 47% placebo

Only 81 mg of aspirin significantly different from placebo

Non significant trend toward more adverse effect in aspirin groups than placebo groups

#3

• aspirin 300 mg QD lowered risk of right-sided adenomas (RR=0.75)